458 Differences of Complement Activation Profile between Type I and Type II of Hereditary Angioedema Due to C1-inhibitor Deficiency

of the attacks. Safety was assessed in terms of adverse events. All participants gave written informed consent. Results: There were 21 acute attacks, 14 for icatibant and 7 for FFP. The median time to onset of symptoms relief was 27 and 45 minutes for icatibant and FFP respectively (P 1⁄4 0.106). The median time to complete resolution of all simptoms was 240 and 2880 minutes respectively for icatibant and FFP (P 1⁄4 0.002). All patients with Icatibant experienced generally mild transient injection-site reactions (erythema and swelling, and pain) wich resolved spontaneously without intervention. No drug-related serious adverse events were observed with icatibant and administration of FFP was not associated with infections of human inmunodeficiency virus, or hepatitis virus. Conclusions: Icatibant was effective and generally well tolerated, providing rapid regression of symptoms associated with acute HAE attacks at all anatomic sites.